

# Regulators of homologous recombination repair as novel targets for cancer treatment

*Małgorzata Krajewska, Rudolf S. N. Fehrmann, Elisabeth G. E. de Vries and Marcel A. T. M. van Vugt\**

*Department of Medical Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands*

## OPEN ACCESS

### Edited by:

Sven Bilke,  
National Cancer Institute/National  
Institutes of Health, USA

### Reviewed by:

Paola Parrella,  
IRCCS Casa Sollievo Della  
Sofferenza, Italy  
Richard Chahwan,  
Albert Einstein College of Medicine,  
USA

### \*Correspondence:

Marcel A. T. M. van Vugt,  
Department of Medical Oncology,  
Cancer Research Center Groningen,  
University Medical Center Groningen,  
University of Groningen, Hanzeplein 1,  
9723GZ Groningen, Netherlands  
[m.vugt@umcg.nl](mailto:m.vugt@umcg.nl)

### Specialty section:

This article was submitted to Cancer  
Genetics, a section of the journal  
*Frontiers in Genetics*

**Received:** 14 January 2015

**Paper pending published:**  
03 February 2015

**Accepted:** 23 February 2015

**Published:** 20 March 2015

### Citation:

Krajewska M, Fehrmann RSN, de  
Vries EGE and van Vugt MATM (2015)  
*Regulators of homologous  
recombination repair as novel targets  
for cancer treatment.*  
*Front. Genet.* 6:96.  
doi: 10.3389/fgene.2015.00096

To cope with DNA damage, cells possess a complex signaling network called the ‘DNA damage response’, which coordinates cell cycle control with DNA repair. The importance of this network is underscored by the cancer predisposition that frequently goes along with hereditary mutations in DNA repair genes. One especially important DNA repair pathway in this respect is homologous recombination (HR) repair. Defects in HR repair are observed in various cancers, including hereditary breast, and ovarian cancer. Intriguingly, tumor cells with defective HR repair show increased sensitivity to chemotherapeutic reagents, including platinum-containing agents. These observations suggest that HR-proficient tumor cells might be sensitized to chemotherapeutics if HR repair could be therapeutically inactivated. HR repair is an extensively regulated process, which depends strongly on the activity of various other pathways, including cell cycle pathways, protein-control pathways, and growth factor-activated receptor signaling pathways. In this review, we discuss how the mechanistic wiring of HR is controlled by cell-intrinsic or extracellular pathways. Furthermore, we have performed a meta-analysis on available genome-wide RNA interference studies to identify additional pathways that control HR repair. Finally, we discuss how these HR-regulatory pathways may provide therapeutic targets in the context of radio/chemosensitization.

**Keywords:** recombination, Cell Cycle, genomic instability, DNA Repair, PARP inhibitors

## Introduction

The DNA in each single cell is constantly exposed to a variety of endogenous and exogenous factors that cause DNA lesions, such as UV light and genotoxic chemicals. In addition, normal physiological processes also significantly contribute to generating DNA damage, including cellular metabolism, which produces reactive oxygen species (ROS) as side-products, and DNA replication, which is not an error-free process. To cope with this constant assault on genomic integrity, cells have evolved a complex signaling network called the ‘DNA damage response’ (DDR). The DDR detects DNA lesions, initiates checkpoints that arrest the ongoing cell cycle and in parallel activates dedicated DNA repair pathways (Jackson and Bartek, 2009). Additionally, when the amount of DNA damage exceeds the repair capacity, DDR signaling will clear damaged cells from the proliferative population through senescence or apoptosis.

Defects in DNA repair are frequently observed in cancer and influence the responsiveness of such cancer cells to therapeutic regimens. Particularly, defects in homologous recombination (HR)-mediated repair of DNA breaks caused by hereditary *BRCA1* and *BRCA2* mutations result in increased sensitivity to DNA damaging agents, particularly platinum-based chemotherapeutics (Tan et al., 2008; Alsop et al., 2012). These observations suggest that modulation of HR repair in HR-proficient tumor cells might constitute an effective manner to sensitize cancers for chemotherapy.

Important in this context is the emerging recognition that DNA break repair is under control of many signaling pathways. Also various HR repair-regulatory pathways have been described and a better understanding of how these pathways control HR may provide insight into how HR repair can be inhibited therapeutically to induce chemosensitization. Therefore, we here present an overview of cell-intrinsic or extracellular pathways that control HR repair. Additionally, we performed a meta-analysis on genome-wide siRNA studies to uncover novel HR regulators. Finally, we will elaborate on the potential therapeutic targets within these pathways.

## Repair of DNA Breaks


Among the various types of DNA lesions, single strand breaks (SSBs) are very prevalent. SSBs can be efficiently repaired through base replacement via base excision repair (BER) or alternatively through removing whole nucleotides via nucleotide excision repair (NER; Caldecott, 2008). Unrepaired SSBs or SSBs that occur during replication can be converted into DNA double strand breaks (DSBs), which are far more toxic. If left unrepaired, only a very limited amount of DNA DSBs is required to cause cell death. Proper repair of these DSBs is therefore crucial for cellular survival. Cells are equipped with two fundamentally different pathways to repair DSBs; non-homologous end-joining (NHEJ) and HR (**Figure 1A**). Non-homologous end-joining can be performed throughout the cell cycle and directly ligates DNA-ends in a non-conservative fashion. Since broken DNA-ends may need cleaning up prior to ligation, NHEJ repair can be mutagenic (a detailed review of NHEJ can be found in Lieber, 2010).

In stark contrast, HR repair utilizes a DNA template for repair with significant sequence homology, and this type of repair is conservative in nature and non-mutagenic (Wyman et al., 2004). Most frequently, sister chromatids are employed for HR, which restricts this type of repair to late S phase and G<sub>2</sub> phases of the cell cycle, after DNA replication has occurred (Johnson and Jasin, 2000; Krejci et al., 2012). During the highly regulated process of HR, three main phases can be distinguished. Firstly, 3'-single-stranded DNA (ssDNA) ends are generated by nucleolytic degradation of the 5'-strands. This first step is catalyzed by endonucleases, including the MRN complex (consisting of Mre11, Rad50, and Nbs1). In a second step, the ssDNA-ends are coated by replication protein A (RPA) filaments. In a third step, RPA is replaced by Rad51 in a *BRCA1*- and *BRCA2*-dependent process, to ultimately perform

the recombinase reaction using a homologous DNA template (**Figure 1B**). More detailed descriptions of HR repair can be found elsewhere (Li and Heyer, 2008; San Filippo et al., 2008). Importantly, HR is not only employed to repair DNA lesions induced by DNA damaging agents, but is also essential for proper chromosome segregation during meiosis. The relevance of HR in these physiological processes is illustrated by its strict requirement during development. Mice lacking key HR genes, such as *Brca1*, *Brca2*, or *Rad51*, display extensive genetic alterations which lead to early embryonic lethality (Gowen et al., 1996; Hakem et al., 1996; Lim and Hasty, 1996; Ludwig et al., 1997; Sharan et al., 1997; Suzuki et al., 1997). Whereas homozygous inactivation of HR genes is usually embryonic lethal, heterozygous inactivation of for instance *BRCA1* and *BRCA2* does not interfere with cellular viability and rather predisposes to cancer, including breast and ovarian cancer (Futreal et al., 1994; Miki et al., 1994; Wooster et al., 1994; Lancaster et al., 1996). The tumors that develop in individuals with heterozygous *BRCA1/2* mutations invariably lose their second *BRCA1/2* allele, indicating that in certain cancers, the absence of *BRCA1/2* is compatible with cellular proliferation. How exactly such tumors cope with their HR defect is currently not fully understood (Elledge and Amon, 2002). What is clear, however, is that these HR-deficient cancers are hypersensitive to various DNA damaging agents, including specific chemotherapeutics (Tan et al., 2008; Alsop et al., 2012). Recent studies have indicated that HR-defective tumors are also exquisitely sensitive to novel agents, such as inhibitors of poly-(ADP-ribose) polymerase (PARP; Bryant et al., 2005; Farmer et al., 2005; Tutt et al., 2010). These insights have prompted the search for cancer-associated mutations in HR genes, to be used for patient stratification for PARP1 inhibitors or other drugs that differentially affect HR-deficient cancers. Additionally, novel components and regulators of the DNA repair machinery are being searched for, to uncover the mechanistic wiring of DNA repair and to uncover potential therapeutic targets for treating cancer.

## Control of HR by the DNA Damage Response

A predominant pathway that controls HR activity is the DDR, which consists of multiple kinase and ubiquitin ligases working in parallel signaling axes to coordinate a cell cycle arrest with DNA repair and induction of apoptosis (Ciccio and Elledge, 2010). Components of the DDR can be functionally classified as (1) sensors of DNA damage, (2) signal transducers, and (3) effectors. Various 'DNA damage sensor' complexes exist in order to detect different types of DNA lesions. In the context of DNA breaks, the Mre11/Rad50/Nbs1 (MRN) complex acts as a sensor for DNA DSBs. The MRN complex recruits and activates the upstream DDR kinase ataxia telangiectasia mutated (ATM) (Lee and Paull, 2007). Subsequently, ATM recruits and phosphorylates all MRN members (Gatei et al., 2000; Lim et al., 2000; Zhao et al., 2000; Yuan et al., 2002; Trenz et al., 2006; Linding et al., 2007; Matsuoka et al., 2007). ATM-mediated phosphorylation of these



HR components is relevant, as mutational inactivation of these ATM phosphorylation sites prevents the formation of the MRN complex at the sites of damage induced by ionizing radiation (Lim et al., 2000; Zhao et al., 2000), and precludes subsequent cell cycle checkpoint activation and DNA repair (Gatei et al., 2011). MRN/ATM activation consequently leads to the recruitment of additional MRN complexes to the DSB site (Kozlov et al., 2011) and goes along with phosphorylation of other, HR components by ATM, including Brca1 (Cortez et al., 1999; Li et al., 2000) and CtIP (Wang et al., 2013).

Although ATM phosphorylates multiple HR components, it remains unclear to what extent ATM is required for HR.

Genetic inactivation of *ATM* in chicken DT40 cells disrupted the formation of irradiation-induced Rad51 and Rad54 foci pointing at impaired HR repair (Morrison et al., 2000; Köcher et al., 2012). However, complete loss of the *Atm* gene in mice did not affect HR capacity in mouse somatic cells in another study (Kass et al., 2013). In contrast, chemical inhibition consistently abrogates HR repair, and points at dominant-negative effects of chemically inhibited ATM (Choi et al., 2010; Kass et al., 2013).

Besides ATM, also ataxia telangiectasia and Rad3 related (ATR) was shown to play a role during HR. In parallel to ATM activation upon DSB formation. The ATR kinase is activated in response to ssDNA, which predominantly occurs

at stalled replication forks (Zou and Elledge, 2003). However, ssDNA is also an intermediate product during HR as a result of DSB processing, and leads to ATR activation in response to DSBs (Jazayeri et al., 2006). Later studies showed that ATR activation not merely is a side-product of DNA-end processing, but is actively involved in the process of HR. Specifically, ATR-dependent hyperphosphorylation of CtIP in response to DSBs is required for CtIP accumulation on the chromatin and extension of DNA-end-resection (Peterson et al., 2013). Combined, it appears that ATM is required for an early resection, whereas ATR is responsible for extensive resection and full checkpoint activation. Although the exact roles of ATM and ATR in the regulation of DNA-end-resection during HR are not yet fully understood, the observation that ATR inhibitors block HR repair warrants further investigation of DDR kinases as therapeutic targets to block DNA repair (Prevo et al., 2012).

Besides regulating the recruitment of HR factors to sites of DNA DSBs, also the actual recombination phase of HR repair is regulated by DDR members. ATM, together with c-Abl, regulates the post-translational modification and assembly of Rad51 filaments (Chen et al., 1999). Furthermore, the downstream checkpoint kinase Chk1 was shown to play a role during recombination. Specifically, Chk1 phosphorylates Rad51 at Thr-309 (Sørensen et al., 2005), which consequently facilitates the assembly of Rad51 nucleofilaments by promoting the displacement of RPA with Rad51 and Rad52 (Sleeth et al., 2007). Importantly, Chk1-depletion resulted in abrogation of Rad51 nuclear foci formation in cells exposed to hydroxyurea, illustrating the functional importance of this interaction (Sørensen et al., 2005). In addition, also Chk2 is involved in regulating HR repair, and Chk2-mediated phosphorylation of Brca1 at Ser-988 was shown to be essential for proper recombination repair (Zhang et al., 2004).

Also negative regulators of DNA-end resection, including 53BP1 and Rif1, are phosphorylated by ATM and are recruited to sites of DNA damage in an ATM-dependent fashion (Escribano-Díaz et al., 2013). Specifically, 53BP1 is phosphorylated by ATM at multiple residues and removal of these sites prevents efficient recruitment of 53BP1 to sites of DNA breaks. In turn, Rif1, which is also phosphorylated by ATM, binds 53BP1 in a phospho-dependent manner and is required to block HR to promote NHEJ repair (Callen et al., 2013; Escribano-Díaz et al., 2013). How exactly DDR signaling can simultaneously promote pro-HR and anti-HR factors is unclear. Very likely, integration of other signaling pathways, including cell cycle kinases, may be important in fine-tuning this response.

Although DDR kinases are clearly important for HR repair, it remains difficult to separate the DNA repair functions from the checkpoint functions of these DDR kinases. For instance, mutation of the multiple ATM phosphorylation sites on Brca1 not only blocks HR repair, but also results in defective intra-S and G<sub>2</sub>/M checkpoint function (Cortez et al., 1999; Xu et al., 1999). Concluding, HR repair appears to be tightly controlled by DDR signaling. However, intense crosstalk and the plethora of proteins

that function both in DDR checkpoint signaling as well as in DNA repair, makes it difficult to pinpoint the exact HR regulatory steps in these pathways.

## Cell Cycle Regulation

Homologous recombination repair is tightly coordinated with cell cycle progression, which is in large part governed by cyclin-dependent kinases (CDKs). Yeast studies provided the first notion that HR repair is limited to S and G<sub>2</sub> phases of the cell cycle and that it is sensitive to chemical CDK inhibition (Aylon et al., 2004). Subsequently, many HR components were shown to be under control of CDKs and that cell cycle kinases, including non-CDKs, control several steps within HR (Aylon et al., 2004; Branzei and Foiani, 2008).

DNA-end resection constitutes the critical decision point to utilize HR or NHEJ for repair of DSBs, and this switch is under prominent control of CDKs. Importantly, if DNA-end resection at sites of DNA breaks has been initiated there is no point of return, because ssDNA cannot be used as a substrate for NHEJ DNA repair (Symington and Gautier, 2011). Clear evidence that break-induced DNA-end resection requires CDK1 was provided in budding yeast (Ira et al., 2004). An important CDK substrate in this process appeared to be Sae2 (in humans called CtIP, encoded by the *RBBP8* gene), which is phosphorylated on Ser-267 in a CDK-dependent fashion (Huertas et al., 2008; Huertas and Jackson, 2009). CDK-mediated phosphorylation of CtIP appeared essential for MRN-mediated DNA-end resection (Limbo et al., 2007; Sartori et al., 2007). In addition to CtIP, also Nbs1 is a CDK target, phosphorylation of which stimulates MRN-dependent end-resection, further underscoring the control of end resection by CDKs (Falck et al., 2012).

Whereas lower eukaryotes have limited numbers of CDKs, mammalian cells have multiple CDKs that can partner with several cyclins (Morgan, 1997), which complicates the analysis of DDR-cell cycle interactions. Nevertheless, initial studies showed that Cdk2 phosphorylation of CtIP stimulates the multimeric interaction between CtIP, Brca1, and the MRN complex (Yu and Chen, 2004; Chen et al., 2008). Specifically, Mre11 is thought to bring Cdk2 and CtIP in close proximity to subsequently promote Cdk2-mediated CtIP phosphorylation (Buis et al., 2012). This interaction has been shown functional, since loss or inhibition of Cdk2 diminishes HR capacity and also results in increased sensitivity to DNA damaging agents (Buis et al., 2012). However, more recent data show that also Cdk1 inactivation decreases HR repair activity (Johnson et al., 2011). These findings may illustrate that different cell types have different CDK activity profiles, and corresponding CDK requirements. Indeed, studies in murine CDK knockout strains illustrated that not one individual CDK but the overall CDKs level highly influences DDR activation in mammalian cells (Murga et al., 2011).

Cyclin-dependent kinases requirements in HR are not restricted to the initiation of DNA-end resection. Even after DNA break resection has been initiated, CDK activity seems to influence HR. Specifically, the stabilization of ssDNA tails is cell

cycle-dependent through CDK-mediated phosphorylation of RPA (Anantha et al., 2007). Phosphorylation of the RPA subunit RPA2 at Ser-13 by Cdk1-cyclin B was observed in response to treatment with the chemotherapeutic drug camptothecin. Mutation of these CDK sites in RPA resulted in increased numbers and longer retention of gamma-H2AX and altered cell cycle distribution, and reduced recruitment of other DNA repair factor to sites of DNA damage (Anantha et al., 2007).

Interestingly, recent studies have revealed that not only CDKs but also their binding partners can influence HR. Two germline specific Cdk2 cyclins (A1 and A2) were shown to potentiate HR repair (Müller-Tidow et al., 2004). Although activity of both cyclin A1 and A2 was reported to be required for HR, only cyclin A1 expression was induced by  $\gamma$ -irradiation in a p53-dependent fashion. Additionally, cyclin D1 emerged as a regulator of HR repair (Jirawatnotai et al., 2011). Upon irradiation, Brca2 recruits cyclin D1 to sites of DNA damage, where it directly interacts with Rad51. Moreover, cyclin D1 appears to be essential for Rad51 function, because decreased levels of cyclin D1 severely affected Rad51 recruitment, and consequently resulted in impaired HR. This requirement appeared independent of the canonical cyclin D-binding partners Cdk4 or Cdk6 (Jirawatnotai et al., 2011).

Cyclin-dependent kinases have also been implicated in the regulation of late-stage processes of HR. After recombination has occurred, sister-chromatids can be connected through so-called Holiday junctions, which are resolved by, among others, the Bloom syndrome, RecQ helicase-like (BLM) helicase. Resolution of Holiday junctions, surprisingly, appears to be negatively regulated by CDKs. Notably, Cdk1-dependent phosphorylation of the BLM helicase during mitosis results in dissociation of BLM from the nuclear matrix (Dutertre et al., 2002). However, the functional consequences of this regulation for HR fidelity still remain unclear. Also Brca2 was shown to be negatively regulated by CDKs. Phosphorylation of Brca2 at Ser-3291 within its C-terminal domain prevents the Brca2–Rad51 interaction and thus impairs Rad51-mediated foci formation (Esashi et al., 2005). The phosphorylation of Brca2 at Ser-3291 appears to depend on Cdk1, since chemical inhibition of Cdk1 activity diminishes Brca2-Ser-3291 phosphorylation (Krajewska et al., 2013). In line with Cdk1 activity being most prevalent during mitosis, this mechanism may functionally restrict HR to those phases of the cell cycle when sister chromatids are available for HR repair. Notably, mitotic inactivation of HR can be exploited using Wee1 inhibitors that can aberrantly activate Cdk1. This results in a block in HR repair, underscoring that CDKs not only activate HR during S-phase, but also block HR during mitosis.


Beyond the CDK-mediated regulation of HR, also other cell cycle kinases were shown to influence HR fidelity. Polo-like kinase 1 (Plk1), for instance, which is required for mitotic entry and mitotic progression (van Vugt and Medema, 2005) was shown to regulate HR. In concert with the cell cycle kinase Casein kinase-2 (CK2), Plk1 phosphorylates Rad51 at Ser-14, which is required for the Rad51 filament formation (Yata et al., 2012). Subsequently, CK2 phosphorylates Rad51 at Thr-13 to enhance the interaction between Rad51 and Nbs1 and to facilitate Rad51 recruitment to sites of DNA damage (Yata et al., 2012). In addition to a direct regulation

of Rad51, Plk1 binds, and phosphorylates Brca2 (Lin et al., 2003). This interaction appears to be abrogated after DNA damage induction, suggesting that Plk1 may also negatively influence HR repair. Additionally, Plk3 was implicated in the regulation of DNA break repair through modification of CtIP (Barton et al., 2014). In addition, cells lacking Plk3 were shown to be sensitive to PARP inhibitors, which suggests a role for Plk3 in the HR repair (Turner et al., 2008). However, the exact role for Plk3 within the HR machinery needs to be elucidated. Combined, these data imply that cell cycle kinases other than CDKs are required to properly activate HR repair as well as control its silencing when appropriate (**Figure 2**).

## Protein Stability Control

As for all cellular pathways, correct protein folding is essential for proper execution of DNA repair. Protein folding is mediated by so-called ‘protein-stability control’ pathways, controlled by heat-shock protein (HSP) family members (Lindquist and Craig, 1988). Among their many client proteins, several cell cycle control, and DNA repair components appear to be under control of these molecular chaperons. Specifically, Hsp90 appears to control the stabilization, folding, and activation of key HR repair signaling proteins. Most prominently, inhibition of Hsp90 using 17-AAG resulted in Brca2 destabilization (Noguchi et al., 2006; Dungey et al., 2009; **Figure 2**). In line with blocking Brca2 function, Hsp90 inhibition delayed Rad51 filament formation (Noguchi et al., 2006) and resulted in radiosensitization, which was enhanced by the addition of PARP inhibitors (Dungey et al., 2009). Later studies using the more potent Hsp90 inhibitor NVP-AUY922 confirmed these HR defects and described potent radiosensitizing effects *in vivo* (Zaidi et al., 2012).

The observations that Brca2 depends heavily on protein-stability chaperons have initiated investigations to see whether Brca2 could be destabilized by mild hyperthermia. Indeed, Brca2 is efficiently but transiently destabilized by a short-term cellular hyperthermia (41–42.5°C; Krawczyk et al., 2011). As a consequence, hyperthermia blocked the recruitment of Rad51 to sites of DNA damage and led to impaired HR (Krawczyk et al., 2011). These HR defects coincided with radiosensitization and increased sensitivity for PARP inhibitors *in vitro* and *in vivo* (Krawczyk et al., 2011). Clearly, these findings offer clinical opportunities, since it allows local induction of HR deficiency, which could be used to sensitize tumors for concomitant radiotherapy and PARP inhibitor treatment (Eppink et al., 2012). In addition, the observed Brca2 destabilization offers an appealing explanation for the earlier observed radio- and chemosensitizing effects of hyperthermia, both pre-clinically and clinically (Overgaard et al., 1995; Vernon et al., 1996; Sneed et al., 1998; van der Zee et al., 2000). However, it should be noted that defective HR through Brca2 inactivation does not explain the entire radiosensitizing effect of hyperthermia. Using isogenic cell lines with defects in various repair pathways, HR only partially contributed (Kampinga et al., 2004). In addition,



effects of hyperthermia were observed in all cycle phases, which does not support the cell cycle-restricted action of HR repair, suggesting additional targets for hyperthermia in DNA repair (Dewey et al., 1978; Kim et al., 1978). Summarizing, current data support the protein-stability machinery as a feasible therapeutic target to decrease HR capacity, either using Hsp90 inhibitors or through mild hyperthermia. Further, these results warrant clinical studies to combine these approaches with genotoxic therapies that are especially effective in HR-deficient cancers, including PARP inhibitors and platinum-containing chemotherapeutics.

In addition to control of HR DNA repair by HSPs, multiple other enzymes have been to control the stability of DNA repair components. Classically, modification of proteins with ubiquitin has been linked to protein-stability control (Hershko and Ciechanover, 1998). Within the DDR, however, ubiquitination (as well as SUMOylation) have been shown primarily with activation and protein complex formation (Jackson and Durocher, 2013). However,

recently the key HR component CtIP was shown to be ubiquitinated by the APC/C-Cdh1 in a cell cycle and DNA damage-dependent fashion (Lafranchi et al., 2014). Whether the APC/C-Cdh1 controls other DDR proteins upon DNA damage, and whether this affects DNA repair needs further investigation.

## Regulation of HR Repair by Growth Factor Receptor Signaling

Growth hormone receptor pathways encompass multiple signaling cascades, controlling many cellular processes including proliferation, cellular survival, and migration. These pathways, including the epidermal growth factor receptor (EGFR) pathway, are frequently hyperactivated in cancers through mutation or amplification and constitute so-called 'oncogenic drivers' (Sharma et al., 2007). However, part of their oncogenic potential may also be explained by promoting DNA repair. Indeed,

growth hormone receptor signaling contributes to increased resistance to radio- or chemotherapy, which likely is related to modulation of DNA repair (Mukherjee et al., 2009). With growth factor receptors being oncogenic drivers, multiple therapeutics have been clinically developed to target growth factor receptors (including antibodies and small molecule inhibitors targeting the EGFR, HER2, and IGF1R). When tested in combination with chemo-radiotherapy, these agents appear to improve responses to radio- and chemotherapy in several cancer types (Huang and Harari, 2000; Bonner et al., 2006). Furthermore, small molecule tyrosine inhibitors that ablate kinase activity of oncogenic variants of these receptors (including erlotinib and gefitinib) have clinical benefit in combination with chemotherapeutics in multiple pre-clinical and clinical studies (Moyer et al., 1997; Knight et al., 2004; Mellingshoff et al., 2005; Quatralo et al., 2011).

Since growth factor receptors control various downstream pathways related to growth and survival, it has remained difficult to pinpoint the influence of growth factor receptor signaling on DNA repair. In addition, it is not completely clear through which mechanism(s) growth factor receptor signaling influences DNA repair, and which DNA repair subtypes are actually modulated by such pathways. In the context of DNA DSB repair, both NHEJ as well as HR were shown to be under control of growth hormone receptor-mediated signaling. Treatment of cells with EGF was shown to increase levels of NHEJ as well as HR (Golding et al., 2009; Myllynen et al., 2011). In the context of promoting NHEJ, the EGFR was reported to associate with the catalytic subunit of DNA-PK, an essential NHEJ component (Liccardi et al., 2011). Additionally, nuclear localization of the EGFR required for DNA repair stimulation, occurs through its interaction with DNA-PK (Liccardi et al., 2011). Additionally, stimulation of the EGFR or the insulin-like growth factor receptor 1 (IGF1R) also elevates levels of HR repair (Golding et al., 2009; Myllynen et al., 2011). Concerning the role of the EGFR in HR repair, it was shown that EGFR activity is required for Brca1 localization to the nucleus (Li et al., 2008). Consequently, blocking the EGFR using erlotinib prevents nuclear Brca1 localization, interferes with Rad51 recruitment to sites of DNA damage and attenuates HR repair (Li et al., 2008). Surprisingly, the role of the IGF1R in HR repair appeared to be mechanistically distinct. IGF1R signaling promotes cellular trafficking of Rad51 through a direct interaction between the insulin receptor substrate-1 (IRS-1), which is recruited to sites of DNA lesions in response to DNA damage (Trojanek et al., 2003). In line with this observation, blocking IGF1R function through deletion of the *Igf1r* gene in mice, or IGF1R depletion ablates IRS-1 phosphorylation, precludes Rad51 translocation to the nucleus and eventually impairs HR repair (Trojanek et al., 2003). Also estrogen-mediated phosphorylation of IRS-1 by the estrogen receptor beta (ER $\beta$ ) affects HR repair (Urbanska et al., 2009). In contrast to insulin receptor signaling and EGFR signaling, surprisingly, ER signaling negatively impacts the Rad51 function, and inhibition of ER $\beta$ -mediated IRS-1 translocation to the nucleus significantly improved DNA repair fidelity and prevented genomic instability (Urbanska et al., 2009). Collectively, multiple growth factor


or hormone receptors impact on DNA repair through direct or indirect interactions with DNA repair proteins, albeit that different receptors may have opposite effects in regulating DNA repair.

Since part of the synergistic effects of combined radio/chemotherapy with targeting growth-factor-activated receptors may be explained by interfering with DNA repair, a synthetic lethal context with agents such as PARP inhibitors may be created. Early preclinical evidence indeed underscores this notion, since EGFR inhibition with lapatinib sensitized breast cancer cells to the PARP inhibitor ABT-888 *in vitro* (Nowshen et al., 2012). In addition, therapeutic targeting of the PI3 kinase, which operates downstream of the EGFR and IGF1R efficiency blocked HR repair through down regulation of both Brca1 and Brca2 and sensitized cells for PARP inhibition (Ibrahim et al., 2012). Concluding, HR DNA repair is not just a cell-intrinsic repair mechanism. Many pathways, including growth factor-activated pathways, were shown to regulate HR, providing a rationale for combined inhibition of growth factor activated pathways with DNA damaging agents.

## Novel Regulators of Homologous Recombination

The development of fluorescence-based reporter systems to read out HR efficiency (Pierce et al., 1999) has enabled high-throughput microscopy studies to uncover novel regulators of HR in mammalian cells. Two important studies have taken a genome-wide approach to identify genes that are required for HR repair (Słabicki et al., 2010; Adamson et al., 2012). Many of the identified genes from these studies are highly conserved and also appear to be essential for HR in single-cell organisms such as yeast, including *BRCA1*, *BRCA2*, and *RAD51* (McKinney et al., 2013). In addition to these well-known HR components, novel HR regulators were identified. Notably, genes that control post-transcriptional processing of RNA, including mRNA splicing, were found to control HR repair (Adamson et al., 2012). For instance, depletion of the RNA binding protein RBMX led to diminished Brca2 levels and a consequent failure to recruit Rad51 to sites of DNA damage. Additionally, a putative helicase SPG48 is required for HR repair, although it remains mechanistically unclear which step of HR it controls (Słabicki et al., 2010). The availability of two independent genome-wide siRNA screens for genes that regulate HR allowed us to compare these data sets and identify common pathways and genes. To this end, we applied Gene-Set Enrichment Analysis (GSEA; Subramanian et al., 2005) to uncover additional pathways that modify HR repair, of which targeting could have therapeutic potential (Figures 3A,B). Four well-known pathway databases were used for enrichment analysis, KEGG, Biocarta, Reactome, and GeneOntology (Figure 3C).

The most striking enrichment was identified in genes that participate in proteasome or RNA biology. These findings match earlier reports demonstrating that proteasome inhibition sensitizes tumor cells to DNA damaging agents, including crosslinking agents, and radiation (Pajonk et al., 2000). Initially,



**FIGURE 3 | Pathways involved in homologous recombination repair of DSBs. (A,B)** Analysis of the data from genome-wide siRNA screens. Data were adapted from published studies (Slabicki et al., 2010, **A**) and (Adamson et al., 2012, **B**). In these studies HR efficiency was assessed using DR-GFP assay in HeLa cells (left) and in DR-U2OS cells (right). Relative HR scores in Z-score (left panel) and ‘Relative HR score’ (right panel) are indicated for genes with an established role in HR: *BRCA1*,

*BRCA2*, *TP53BP1*, *NUP153*, and *RAD51*. **(C)** Gene-Set Enrichment Analysis (GSEA) was performed on the data presented in **(A,B)**. Four pathway databases were used for enrichment analysis: KEGG, Biocarta, Reactome, and GeneOntology. Results of the GSEA on the dataset by Slabicki et al. (2010) are represented in light gray, and results on the dataset by Adamson et al. (2012) are represented in dark gray. Red dashed line indicates 95% confidence interval.



these effects were explained by proteasome-mediated control of pro-apoptotic p53 signaling (Vaziri et al., 2005). Thereafter, a more direct role for the proteasome in controlling DNA repair was identified. Inhibition of the proteasome using MG132 or bortezomib, or genetic inactivation of proteasome components blocked the recruitment of DNA repair components FancD2, Brca1, and Rad51, whereas upstream the DDR signaling components H2AX and Mdc1 appeared unaffected (Jacquemont and Taniguchi, 2007; Cron et al., 2013). Due to defective recruitment of these HR factors, inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells (Murakawa et al., 2007). In line with this notion, proteasome inhibition using bortezomib was shown to prevent repair of PARP-inhibitor induced DNA breaks (Neri et al., 2011). Importantly, combined treatment with bortezomib and the PARP inhibitor ABT-888 resulted in sustained levels of H2AX, with defective recruitment of HR repair components leading to enhanced killing of tumor cells. Combined, these results show that the proteasome is involved in HR repair and that therapeutic targeting of the proteasome, using for instance bortezomib, can be used to induce 'BRCAness' in tumor cells. Also, the fact that genome-wide *in vitro* assays identified the proteasome as a system that controls HR repair argues that other HR-controlling pathways may also be uncovered using these approaches.

Among the enriched pathways involved in HR repair, RNA processing was highly abundant (Figure 3C), as is matched by the recent identification of RNA-modifying enzymes as regulators of HR (Adamson et al., 2012). In mammalian cells, not much data exist that mechanistically link RNA to HR repair. However, some data from model organisms have provided evidence that RNA processing is involved in DNA repair. Using genetic analysis in *Drosophila*, the RNA splice factor SPF45 was shown to combine a function in RNA splicing and protection against DNA damage caused by MMS exposure (Chaouki and Salz, 2006). Notably, mutations that abolish the RNA splicing function also fail to protect against DNA damage-induced toxicity. Mechanistically, SPF45 appears to interact with Rad201, a member of the RecQ/Rad51 family (Chaouki and Salz, 2006). An unbiased proteomic screening in budding yeast underscored the link between RNA metabolism and DNA repair, for instance by identifying the splicing factor PRP19, as being involved in the DDR (Smolka et al., 2007). In human cells, a mRNA splicing complex consisting of Pso4, Cdc5L, and Psf27 was found to interact with the WNR DNA helicase and was identified to be required for interstrand cross-link repair (Zhang et al., 2005; Figure 2). Additionally, Dicer and Drosha RNA products produced from sites of DNA damage were shown to be required for proper DDR signaling (Francia et al., 2012). Again, large-scale proteomic analysis confirmed this notion, and identified multiple factors involved in RNA metabolism, illustrating the intricate connection between RNA splicing and DNA repair (Matsuoka et al., 2007). Part of this relationship can be explained by the observation that uncontrolled mRNA maturation disturbs the DNA-RNA interaction and have deleterious effects on genomic stability (Montecucco and Biamonti, 2013).

## Targeting HR-Deficient Tumors Clinically

In oncology, many radio- and/or chemotherapeutic regimens are used in daily practice, which induce high levels of DNA damage directly or indirectly. These therapeutic regimens often induce interstrand DNA crosslinks and DNA DSBs, of which accumulation is very cytotoxic and requires HR for faithful repair. Consequently, tumors in which HR repair is compromised due to mutations or epigenetic silencing of HR repair genes are generally more sensitive to specific DNA damage-inducing factors. Extensive *in vitro* and *in vivo* preclinical studies provided compelling evidence that HR defects are causally related to the vulnerability of such cancer cells to certain DNA damaging chemotherapeutics and radiotherapy. Studies comparing various neo-adjuvant chemotherapeutic regimens in *BRCA1* mutant breast cancers, found that highest response rates were observed with neo-adjuvant cisplatin chemotherapy (Byrski et al., 2010), which increased progression free survival (Byrski et al., 2008). In analogy, responses of ovarian cancer lines to cisplatin were also influenced by their *BRCA1/2* mutation status as well as the status of related HR genes (Taniguchi et al., 2003). These data indicate that inactivation of the HR pathway, either through germ-line or somatic *BRCA1/2* inactivation is linked to increased sensitivity to DNA damaging therapeutics, notably platinum-based agents.

The fact that DNA repair defects through cancer-associated mutations lead to specific vulnerabilities is exploited in synthetic lethal approaches: mutation or inhibition of two separate pathways leads to cell death, whereas loss of function in either one of these pathways does not affect viability. The prototypical synthetic lethal interaction was described for the *BRCA1* and *BRCA2* mutations, which are synthetic lethal with loss of PARP-1 (Bryant et al., 2005; Farmer et al., 2005). Mechanistically, inhibition of PARP1 blocks BER and leads to accumulation of SSBs, which are converted to DSBs in replicating cells (Bryant et al., 2005; Farmer et al., 2005). These DSBs cannot be properly repaired due to the HR defect in *BRCA1/2* mutant cells, which results in cytotoxicity. Recent studies provided evidence that PARP is additionally required for restarting of stalled replication forks (Bryant et al., 2009; Petermann et al., 2010). PARP1 accumulates at stalled replication forks and recruits Mre11 to catalyze DNA-end processing for replication restart and recombination. As a consequence, PARP inhibition also results in replication forks collapse, which again leads to accumulation of toxic DNA structures in HR-deficient cells (Schlacher et al., 2011). The finding that *BRCA1/2* mutant cells are selectively sensitive to PARP inhibition constituted the starting point for several clinical trials and the clinical development of various PARP inhibitors. In 2005, the first phase I clinical study investigating a PARP inhibitor (Olaparib, AZD2281) demonstrated that more than 90% of PARP enzymatic activity could be inhibited, which was well tolerated and did not increase toxicity in the *BRCA1/2* mutation carriers group (Fong et al., 2009). More importantly, this study showed clinical benefit of PARP inhibition in patients with *BRCA1/2* mutations (Fong et al., 2009). This early success prompted the clinical development of various PARP inhibitors as single agents or

as part of combined treatment with DNA damaging agents in phase II clinical trials (Audeh et al., 2010; Tutt et al., 2010). In addition the reported beneficial effect of PARP inhibition in breast and ovarian patients with *BRCA1/2* mutations boosted the interest in this type of therapies for other tumors types, including colon cancers, prostate cancer, and gastric cancer (Barreto-Andrade et al., 2011; Sebastian de Bono et al., 2011; Davidson et al., 2013). Results of preformed or ongoing clinical trials with PARP inhibitors are therefore eagerly awaited.

The preclinical studies and early clinical studies raised high potential for therapeutic use of PARP1 inhibitors, but unfortunately PARP inhibitors have not yet delivered the clinical success that preclinical studies promised. Several findings can be attributed to these discrepancies.

Firstly, it appears difficult to effectively select patients for PARP1 inhibitor treatment. The most straightforward strategy to select patients is to obtain the mutation status of *BRCA1/2* in cancer specimens. However, *BRCA1* or *BRCA2* are not only inactivated through gene mutation, also DNA hypermethylation of the genes is frequently reported for several cancers (Esteller et al., 2000; Rice et al., 2000; Cancer Genome Atlas Research Network, 2011). Patients with hypermethylated *BRCA1/2* genes may benefit from PARP1 inhibitors, but may be missed when only *BRCA1/2* mutations status is analyzed. In contrast, when selection criteria are not sufficiently strict, effects of PARP inhibitors may be missed. For example, some studies included all TNBCs, whereas only a subset of these patients may harbor HR defects, and may therefore have clinical benefit from PARP inhibitors (Gelmon et al., 2011). A straightforward, but labor-intensive solution to successfully implement PARP inhibitors is to functionally assess HR efficiency in fresh tumor biopsies (Willers et al., 2009). Alternatively, measuring consequences of defective HR, such as genome-wide copy number variation analysis using aCGH may identify tumors with defective HR (Vollebergh et al., 2011). Besides selecting *BRCA1/2* mutant tumors, also mutation of other HR genes results in cancers with similar characteristics, including *PALB2* (Rahman et al., 2007) or *RAD51C* (Clague et al., 2011). Mutation of these genes appeared to result in PARP1 inhibitor sensitivity (Loveday et al., 2012; Min et al., 2013). Also novel regulators of HR may be important in this respect, such as the negative regulator of Brca1 called ID4 (Turner et al., 2007). Whether ID4 mutations or mutations in other novel HR components are frequently found in cancers needs to be studied. Clearly, these observations indicate that there is a strong need to reliably identify cancers with defective HR repair, in order to stratify patient for therapies that target HR-deficient cancers, including PARP1 inhibitors.

Secondly, not all PARP inhibitors appear to be very efficient PARP inhibitors *in vivo*. Moreover, some PARP inhibitors have additional effects. For instance, iniparib (BSI-201) also inhibits other enzymes, including GAPDH (Bauer et al., 2002). It is therefore difficult to verify whether observed clinical benefit in phase II study was achieved exclusively due to PARP inhibition.

A third complicating factor in developing PARP inhibitors for HR-deficient cancers, is the recent observation that secondary mutations may dramatically alter the HR defect of *BRCA1/2*

mutation cancers. These secondary mutations can be sub-classified into two categories. The first category consists of intragenic secondary mutations in affected *BRCA1* or *BRCA2* alleles that have been described to restore their reading frame (Sakai et al., 2008; Swisher et al., 2008) and result in resistance to cisplatin. The second category involves secondary mutations in other genes, which have been shown to reverse a HR defect. Mutation of *TP53BP1* for instance, reverses the HR defect in *BRCA1* mutant cancers and render these cancers resistant to PARP1 inhibition. More recently, *Rif1* was shown to counteract Brca1 function, and *Rif1* mutations could rescue the genomic instability of mouse *Brca1*<sup>-/-</sup> cells (Bouwman et al., 2010; Chapman et al., 2012; Di Virgilio et al., 2013; Escobano-Díaz et al., 2013; Feng et al., 2013; Zimmermann et al., 2013). Whether *Rif1* mutations also account for therapy resistance in *BRCA1* mutant cancers remains to be tested. What is clear is that *BRCA1/2* mutations do not per se reflect a defect in HR, and that functional testing of HR capacity may be required to reliably classify the DNA repair defect in cancers.

## Future Perspectives

If HR function could be locally inhibited in cancer cells, this would allow exploitation of the enhanced sensitivity for platinum-containing chemotherapeutics, radiotherapy, or PARP inhibition. The most straightforward approach would be to directly target HR components. The identification of druggable HR genes is therefore actively being pursued. One approach is to chemically inhibit Rad51, the most downstream HR component. Recent studies making use of high-throughput screens have identified chemical Rad51 inhibitors, which increased the sensitivity of glioblastoma cells to alkylating agents (Quiros et al., 2011), and were shown to sensitize various human cancer cells to DNA crosslinking agents, including mitomycin C (Budke et al., 2012).

In addition to directly targeting HR components, the reports described in this review show that modulation of regulatory pathways controlling HR components may be useful as well to achieve an HR-deficient phenotype and thereby sensitize tumor cells to DNA damaging agents (an overview of cellular pathways that regulate HR repair is presented in **Figure 2**). This has been elegantly shown in pre-clinical studies using cell cycle modulators, hyperthermia, DDR inhibitors and Hsp90 inhibitors. Novel approaches, including genome-wide siRNA screens and proteomic interaction maps, may add novel regulators to this growing list of potential therapeutic targets that control HR and warrant translation of these novel targets to uncover their therapeutic potential.

## Acknowledgments

This work was financially supported by grants from the Netherlands Organization for Scientific Research (NWO-VIDI grant 916-76062 to MV), a grant from the Van der Meer-Boerema Foundation to MK and grants from the Dutch Cancer Society (RUG 2011-5093 to MV and RUG 2013-5960 to RF).

## References

- Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W., and Elledge, S. J. (2012). A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. *Nat. Cell Biol.* 14, 318–328. doi: 10.1038/ncb2426
- Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., et al. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J. Clin. Oncol.* 30, 2654–2663. doi: 10.1200/JCO.2011.39.8545
- Anantha, R. W., Vassin, V. M., and Borowiec, J. A. (2007). Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair. *J. Biol. Chem.* 282, 35910–35923. doi: 10.1074/jbc.M704645200
- Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 376, 245–251. doi: 10.1016/S0140-6736(10)60893-8
- Aylon, Y., Liefshitz, B., and Kupiec, M. (2004). The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. *EMBO J.* 23, 4868–4875. doi: 10.1038/sj.emboj.7600469
- Barreto-Andrade, J. C., Efimova, E. V., Mauceri, H. J., Beckett, M. A., Sutton, H. G., Darga, T. E., et al. (2011). Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. *Mol. Cancer Ther.* 10, 1185–1193. doi: 10.1158/1535-7163.MCT-11-0061
- Barton, O., Naumann, S. C., Diemer-Biehls, R., Künzel, J., Steinlage, M., Conrad, S., et al. (2014). Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1. *J. Cell Biol.* 206, 877–894. doi: 10.1083/jcb.201401146
- Bauer, P. I., Mendeleyeva, J., Kirsten, E., Comstock, J. A., Hakam, A., Buki, K. G., et al. (2002). Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. *Biochem. Pharmacol.* 63, 455–462. doi: 10.1016/S0006-2952(01)00872-3
- Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* 354, 567–578. doi: 10.1056/NEJMoa053422
- Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., et al. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat. Struct. Mol. Biol.* 17, 688–695. doi: 10.1038/nsmb.1831
- Branzei, D., and Foiani, M. (2008). Regulation of DNA repair throughout the cell cycle. *Nat. Rev. Mol. Cell Biol.* 9, 297–308. doi: 10.1038/nrm2351
- Bryant, H. E., Petermann, E., Schultz, N., Jemth, A.-S., Loseva, O., Issaeva, N., et al. (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. *EMBO J.* 28, 2601–2615. doi: 10.1038/emboj.2009.206
- Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434, 913–917. doi: 10.1038/nature03443
- Budke, B., Logan, H. L., Kalin, J. H., Zelivianskaia, A. S., Cameron McGuire, W., Miller, L. L., et al. (2012). RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. *Nucleic Acids Res.* 40, 7347–7357. doi: 10.1093/nar/gks353
- Buis, J., Stoneham, T., Spehalski, E., and Ferguson, D. O. (2012). Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2. *Nat. Struct. Mol. Biol.* 19, 246–252. doi: 10.1038/nsmb.2212
- Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. (2008). Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. *Breast Cancer Res. Treat.* 108, 289–296. doi: 10.1007/s10549-007-9600-1
- Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J. Clin. Oncol.* 28, 375–379. doi: 10.1200/JCO.2008.20.7019
- Caldecott, K. W. (2008). Single-strand break repair and genetic disease. *Nat. Rev. Genet.* 9, 619–631. doi: 10.1038/nrg2380
- Callen, E., Di Virgilio, M., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H.-T., et al. (2013). 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. *Cell* 153, 1266–1280. doi: 10.1016/j.cell.2013.05.023
- Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. *Nature* 474, 609–615. doi: 10.1038/nature10166
- Chaouki, A. S., and Salz, H. K. (2006). Drosophila SPF45: a bifunctional protein with roles in both splicing and DNA repair. *PLoS genet.* 2:e178. doi: 10.1371/journal.pgen.0020178
- Chapman, J. R., Taylor, M. R. G., and Boulton, S. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. *Mol. Cell* 47, 497–510. doi: 10.1016/j.molcel.2012.07.029
- Chen, G., Yuan, S. S., Liu, W., Xu, Y., Trujillo, K., Song, B., et al. (1999). Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. *J. Biol. Chem.* 274, 12748–12752. doi: 10.1074/jbc.274.18.12748
- Chen, L., Nievera, C. J., Lee, A. Y.-L., and Wu, X. (2008). Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. *J. Biol. Chem.* 283, 7713–7720. doi: 10.1074/jbc.M710245200
- Choi, S., Gamper, A. M., White, J. S., and Bakkenist, C. J. (2010). Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors. *Cell Cycle* 9, 4052–4057.
- Ciccia, A., and Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. *Mol. Cell* 40, 179–204. doi: 10.1016/j.molcel.2010.09.019
- Clague, J., Wilhoite, G., Adamson, A., Bailis, A., Weitzel, J. N., and Neuhausen, S. L. (2011). RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. *PLoS ONE* 6:e25632. doi: 10.1371/journal.pone.0025632
- Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. (1999). Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. *Science* 286, 1162–1166. doi: 10.1126/science.286.5442.1162
- Cron, K. R., Zhu, K., Kushwaha, D. S., Hsieh, G., Merzon, D., Rameseder, J., et al. (2013). Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. *PLoS ONE* 8:e73710. doi: 10.1371/journal.pone.0073710
- Davidson, D., Wang, Y., Aloyz, R., and Panasci, L. (2013). The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. *Invest. New Drugs* 31, 461–468. doi: 10.1007/s10637-012-9886-7
- Dewey, W. C., Sapareto, S. A., and Betten, D. A. (1978). Hyperthermic radiosensitization of synchronous Chinese hamster cells: relationship between lethality and chromosomal aberrations. *Radiat. Res.* 76, 48–59. doi: 10.2307/3574926
- Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., et al. (2013). Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. *Science* 339, 711–715. doi: 10.1126/science.1230624
- Dungey, F. A., Caldecott, K. W., and Chalmers, A. J. (2009). Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. *Mol. Cancer Ther.* 8, 2243–2254. doi: 10.1158/1535-7163.MCT-09-0201
- Dutertre, S., Sekhri, R., Tintignac, L. A., Onclercq-Delic, R., Chatton, B., Jaulin, C., et al. (2002). Dephosphorylation and subcellular compartment change of the mitotic Bloom's syndrome DNA helicase in response to ionizing radiation. *J. Biol. Chem.* 277, 6280–6286. doi: 10.1074/jbc.M105735200
- Elledge, S. J., and Amon, A. (2002). The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. *Cancer Cell* 1, 129–132. doi: 10.1016/S1535-6108(02)00041-7
- Eppink, B., Krawczyk, P. M., Stap, J., and Kanaar, R. (2012). Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. *Int. J. Hyperthermia* 28, 509–517. doi: 10.3109/02656736.2012.695427
- Esashi, F., Christ, N., Gannon, J., Liu, Y., Hunt, T., Jasin, M., et al. (2005). CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. *Nature* 434, 598–604. doi: 10.1038/nature03404
- Escribano-Díaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., et al. (2013). A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol. Cell* 49, 872–883. doi: 10.1016/j.molcel.2013.01.001
- Esteller, M., Silva, J. M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., et al. (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. *J. Natl. Cancer Inst.* 92, 564–569. doi: 10.1093/jnci/92.7.564

- Falck, J., Forment, J. V., Coates, J., Mistrik, M., Lukas, J., Bartek, J., et al. (2012). CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. *EMBO Rep.* 13, 561–568. doi: 10.1038/embor.2012.58
- Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 434, 917–921. doi: 10.1038/nature03445
- Feng, L., Fong, K.-W., Wang, J., Wang, W., and Chen, J. (2013). RIF1 counteracts BRCA1-mediated end resection during DNA repair. *J. Biol. Chem.* 288, 11135–11143. doi: 10.1074/jbc.M113.457440
- Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N. Engl. J. Med.* 361, 123–134. doi: 10.1056/NEJMoa0900212
- Francia, S., Michelini, F., Saxena, A., Tang, D., de Hoon, M., Anelli, V., et al. (2012). Site-specific DICER and DROSHA RNA products control the DNA-damage response. *Nature* 488, 231–235. doi: 10.1038/nature11179
- Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., et al. (1994). BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 266, 120–122. doi: 10.1126/science.7939630
- Gatei, M., Jakob, B., Chen, P., Kijas, A. W., Becherel, O. J., Gueven, N., et al. (2011). ATM protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell cycle control. *J. Biol. Chem.* 286, 31542–31556. doi: 10.1074/jbc.M111.258152
- Gatei, M., Young, D., Cerosaletti, K. M., Desai-Mehta, A., Spring, K., Kozlov, S., et al. (2000). ATM-dependent phosphorylation of nibrin in response to radiation exposure. *Nat. Genet.* 25, 115–119. doi: 10.1038/75508
- Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., et al. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 12, 852–861. doi: 10.1016/S1470-2045(11)70214-5
- Golding, S. E., Morgan, R. N., Adams, B. R., Hawkins, A. J., Povirk, L. F., and Valerie, K. (2009). Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. *Cancer Biol. Ther.* 8, 730–738. doi: 10.4161/cbt.8.8.7927
- Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., and Koller, B. H. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat. Genet.* 12, 191–194. doi: 10.1038/ng0296-191
- Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., et al. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. *Cell* 85, 1009–1023. doi: 10.1016/S0092-8674(00)81302-1
- Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. *Annu. Rev. Biochem.* 67, 425–479. doi: 10.1146/annurev.biochem.67.1.425
- Huang, S. M., and Harari, P. M. (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. *Clin. Cancer Res.* 6, 2166–2174.
- Huertas, P., Cortés-Ledesma, F., Sartori, A. A., Aguilera, A., and Jackson, S. P. (2008). CDK targets Sae2 to control DNA-end resection and homologous recombination. *Nature* 455, 689–692. doi: 10.1038/nature07215
- Huertas, P., and Jackson, S. P. (2009). Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. *J. Biol. Chem.* 284, 9558–9565. doi: 10.1074/jbc.M808906200
- Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., et al. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. *Cancer Discov.* 2, 1036–1047. doi: 10.1158/2159-8290.CD-11-0348
- Ira, G., Pelliccioli, A., Balijja, A., Wang, X., Fiorani, S., Carotenuto, W., et al. (2004). DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. *Nature* 431, 1011–1017. doi: 10.1038/nature02964
- Jackson, S. P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. *Nature* 461, 1071–1078. doi: 10.1038/nature08467
- Jackson, S. P., and Durocher, D. (2013). Regulation of DNA damage responses by ubiquitin and SUMO. *Mol. Cell* 49, 795–807. doi: 10.1016/j.molcel.2013.01.017
- Jacquemont, C., and Taniguchi, T. (2007). Proteasome function is required for DNA damage response and fanconi anemia pathway activation. *Cancer Res.* 67, 7395–7405. doi: 10.1158/0008-5472.CAN-07-1015
- Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. *Nat. Cell Biol.* 8, 37–45. doi: 10.1038/ncb1337
- Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, E., et al. (2011). A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. *Nature* 474, 230–234. doi: 10.1038/nature10155
- Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., et al. (2011). Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. *Nat. Med.* 17, 875–882. doi: 10.1038/nm.2377
- Johnson, R. D., and Jasin, M. (2000). Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. *EMBO J.* 19, 3398–3407. doi: 10.1093/emboj/19.13.3398
- Kampinga, H. H., Dynlacht, J. R., and Dikomey, E. (2004). Mechanism of radiosensitization by hyperthermia (> or = 43 degrees C) as derived from studies with DNA repair defective mutant cell lines. *Int. J. Hyperthermia* 20, 131–139. doi: 10.1080/02656730310001627713
- Kass, E. M., Helgadottir, H. R., Chen, C.-C., Barbera, M., Wang, R., Westermarck, U. K., et al. (2013). Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. *Proc. Natl. Acad. Sci. U.S.A.* 110, 5564–5569. doi: 10.1073/pnas.1216824110
- Kim, J. H., Hahn, E. W., and Tokita, N. (1978). Combination hyperthermia and radiation therapy for cutaneous malignant melanoma. *Cancer* 41, 2143–2148.
- Knight, L. A., Di Nicolantonio, F., Whitehouse, P., Mercer, S., Sharma, S., Glaysher, S., et al. (2004). The in vitro effect of gefitinib (“Iressa”) alone and in combination with cytotoxic chemotherapy on human solid tumours. *BMC Cancer* 4:83. doi: 10.1186/1471-2407-4-83
- Köcher, S., Rieckmann, T., Rohaly, G., Mansour, W. Y., Dikomey, E., Dornreiter, L., et al. (2012). Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase. *Nucleic Acids Res.* 40, 8336–8347. doi: 10.1093/nar/gks604
- Kozlov, S. V., Graham, M. E., Jakob, B., Tobias, F., Kijas, A. W., Tanuji, M., et al. (2011). Autophosphorylation and ATM activation: additional sites add to the complexity. *J. Biol. Chem.* 286, 9107–9119. doi: 10.1074/jbc.M110.204065
- Krajewska, M., Heijink, A. M., Bisselink, Y. J. W. M., Seinstra, R. I., Silljé, H. H. W., de Vries, E. G. E., et al. (2013). Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. *Oncogene* 32, 3001–3008. doi: 10.1038/ncr.2012.296
- Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H., Odijk, H., et al. (2011). Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. *Proc. Natl. Acad. Sci. U.S.A.* 108, 9851–9856. doi: 10.1073/pnas.1101053108
- Krejci, L., Altmannova, V., Spirek, M., and Zhao, X. (2012). Homologous recombination and its regulation. *Nucleic Acids Res.* 40, 5795–5818. doi: 10.1093/nar/gks270
- Lafranchi, L., de Boer, H. R., de Vries, E. G. E., Ong, S.-E., Sartori, A. A., and van Vugt, M. A. T. M. (2014). APC/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. *EMBO J.* 33, 2860–2879. doi: 10.15252/emboj.201489017
- Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C., et al. (1996). BRCA2 mutations in primary breast and ovarian cancers. *Nat. Genet.* 13, 238–240. doi: 10.1038/ng0696-238
- Lee, J.-H., and Paull, T. T. (2007). Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. *Oncogene* 26, 7741–7748. doi: 10.1038/sj.onc.1210872
- Li, L., Wang, H., Yang, E. S., Arteaga, C. L., and Xia, F. (2008). Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. *Cancer Res.* 68, 9141–9146. doi: 10.1158/0008-5472.CAN-08-1127
- Li, S., Ting, N. S., Zheng, L., Chen, P. L., Ziv, Y., Shiloh, Y., et al. (2000). Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. *Nature* 406, 210–215. doi: 10.1038/35018134
- Li, X., and Heyer, W.-D. (2008). Homologous recombination in DNA repair and DNA damage tolerance. *Cell Res.* 18, 99–113. doi: 10.1038/cr.2008.1

- Liccardi, G., Hartley, J. A., and Hochhauser, D. (2011). EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. *Cancer Res.* 71, 1103–1114. doi: 10.1158/0008-5472.CAN-10-2384
- Lieber, M. R. (2010). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu. Rev. Biochem.* 79, 181–211. doi: 10.1146/annurev.biochem.052308.093131
- Lim, D. S., and Hastay, P. (1996). A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. *Mol. Cell. Biol.* 16, 7133–7143.
- Lim, D. S., Kim, S. T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H., et al. (2000). ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. *Nature* 404, 613–617. doi: 10.1038/35007091
- Limbo, O., Chahwan, C., Yamada, Y., de Bruin, R. A. M., Wittenberg, C., and Russell, P. (2007). Ctp1 is a cell-cycle-regulated protein that functions with Mre11 complex to control double-strand break repair by homologous recombination. *Mol. Cell* 28, 134–146. doi: 10.1016/j.molcel.2007.09.009
- Lin, H.-R., Ting, N. S. Y., Qin, J., and Lee, W.-H. (2003). M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. *J. Biol. Chem.* 278, 35979–35987. doi: 10.1074/jbc.M210659200
- Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. T. M., Jørgensen, C., Miron, I. M., et al. (2007). Systematic discovery of in vivo phosphorylation networks. *Cell* 129, 1415–1426. doi: 10.1016/j.cell.2007.05.052
- Lindquist, S., and Craig, E. A. (1988). The heat-shock proteins. *Annu. Rev. Genet.* 22, 631–677. doi: 10.1146/annurev.gen.22.120188.003215
- Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D., et al. (2012). Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat. Genet.* 44, 475–476. doi: 10.1038/ng.2224
- Ludwig, T., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. *Genes Dev.* 11, 1226–1241. doi: 10.1101/gad.11.10.1226
- Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 316, 1160–1166. doi: 10.1126/science.1140321
- McKinney, J. S., Sethi, S., Tripp, J. D., Nguyen, T. N., Sanderson, B. A., Westmoreland, J. W., et al. (2013). A multistep genomic screen identifies new genes required for repair of DNA double-strand breaks in *Saccharomyces cerevisiae*. *BMC Genomics* 14:251. doi: 10.1186/1471-2164-14-251
- Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N. Engl. J. Med.* 353, 2012–2024. doi: 10.1056/NEJMoa051918
- Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266, 66–71. doi: 10.1126/science.7545954
- Min, A., Im, S.-A., Yoon, Y.-K., Song, S.-H., Nam, H.-J., Hur, H.-S., et al. (2013). RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. *Mol. Cancer Ther.* 12, 865–877. doi: 10.1158/1535-7163.MCT-12-0950
- Montecucco, A., and Biamonti, G. (2013). Pre-mRNA processing factors meet the DNA damage response. *Front. Genet.* 4:102. doi: 10.3389/fgene.2013.00102
- Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. *Annu. Rev. Cell Dev. Biol.* 13, 261–291. doi: 10.1146/annurev.cellbio.13.1.261
- Morrison, C., Sonoda, E., Takao, N., Shinohara, A., Yamamoto, K., and Takeda, S. (2000). The controlling role of ATM in homologous recombinational repair of DNA damage. *EMBO J.* 19, 463–471. doi: 10.1093/emboj/19.3.463
- Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., et al. (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. *Cancer Res.* 57, 4838–4848.
- Mukherjee, B., McEllin, B., Camacho, C. V., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S., et al. (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. *Cancer Res.* 69, 4252–4259. doi: 10.1158/0008-5472.CAN-08-4853
- Müller-Tidow, C., Ji, P., Diederichs, S., Potratz, J., Bäumer, N., Köhler, G., et al. (2004). The cyclin A1-CDK2 complex regulates DNA double-strand break repair. *Mol. Cell. Biol.* 24, 8917–8928. doi: 10.1128/MCB.24.20.8917-8928.2004
- Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimura, H., et al. (2007). Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. *Cancer Res.* 67, 8536–8543. doi: 10.1158/0008-5472.CAN-07-1166
- Murga, M., Campaner, S., López-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., et al. (2011). Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. *Nat. Struct. Mol. Biol.* 18, 1331–1335. doi: 10.1038/nsmb.2189
- Myllynen, L., Rieckmann, T., Dahm-Daphi, J., Kasten-Pisula, U., Petersen, C., Dikomey, E., et al. (2011). In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. *Radiother. Oncol.* 101, 147–151. doi: 10.1016/j.radonc.2011.05.046
- Neri, P., Ren, L., Gratton, K., Stebner, E., Johnson, J., Klimowicz, A., et al. (2011). Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors. *Blood* 118, 6368–6379. doi: 10.1182/blood-2011-06-363911
- Noguchi, M., Yu, D., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., et al. (2006). Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. *Biochem. Biophys. Res. Commun.* 351, 658–663. doi: 10.1016/j.bbrc.2006.10.094
- Newshean, S., Cooper, T., Stanley, J. A., and Yang, E. S. (2012). Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. *PLoS ONE* 7:e46614. doi: 10.1371/journal.pone.0046614
- Overgaard, J., González González, D., Hulshof, M. C., Arcangeli, G., Dahl, O., Mella, O., et al. (1995). Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European society for hyperthermic oncology. *Lancet* 345, 540–543. doi: 10.1016/S0140-6736(95)90463-8
- Pajonk, F., Pajonk, K., and McBride, W. H. (2000). Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. *Int. J. Radiat. Oncol. Biol. Phys.* 47, 1025–1032. doi: 10.1016/S0360-3016(00)00516-2
- Petermann, E., Orta, M. L., Issaeva, N., Schultz, N., and Helleday, T. (2010). Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. *Mol. Cell* 37, 492–502. doi: 10.1016/j.molcel.2010.01.021
- Peterson, S. E., Li, Y., Wu-Baer, F., Chait, B. T., Baer, R., Yan, H., et al. (2013). Activation of DSB processing requires phosphorylation of CtIP by ATR. *Mol. Cell* 49, 657–667. doi: 10.1016/j.molcel.2012.11.020
- Pierce, A. J., Johnson, R. D., Thompson, L. H., and Jasin, M. (1999). XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. *Genes Dev.* 13, 2633–2638. doi: 10.1101/gad.13.20.2633
- Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., et al. (2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. *Cancer Biol. Ther.* 13, 1072–1081. doi: 10.4161/cbt.21093
- Quatrala, A. E., Porcelli, L., Silvestris, N., Colucci, G., Angelo, A., and Azzariti, A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. *Front. Biosci. (Landmark Ed.)* 16:1962–1972. doi: 10.2741/3833
- Quiros, S., Roos, W. P., and Kaina, B. (2011). Rad51 and BRCA2—New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. *PLoS ONE* 6:e27183. doi: 10.1371/journal.pone.0027183
- Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat. Genet.* 39, 165–167. doi: 10.1038/ng1959
- Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., and Futscher, B. W. (2000). Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. *Carcinogenesis* 21, 1761–1765. doi: 10.1093/carcin/21.9.1761
- Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., et al. (2008). Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 451, 1116–1120. doi: 10.1038/nature06633

- San Filippo, J., Sung, P., and Klein, H. (2008). Mechanism of eukaryotic homologous recombination. *Annu. Rev. Biochem.* 77, 229–257. doi: 10.1146/annurev.biochem.77.061306.125255
- Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., et al. (2007). Human CtIP promotes DNA end resection. *Nature* 450, 509–514. doi: 10.1038/nature06337
- Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., and Jasin, M. (2011). Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. *Cell* 145, 529–542. doi: 10.1016/j.cell.2011.03.041
- Sebastian de Bono, J., Sandhu, S., and Attard, G. (2011). Beyond hormone therapy for prostate cancer with PARP inhibitors. *Cancer Cell* 19, 573–574. doi: 10.1016/j.ccr.2011.05.003
- Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., et al. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. *Nature* 386, 804–810. doi: 10.1038/386804a0
- Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. *Nat. Rev. Cancer* 7, 169–181. doi: 10.1038/nrc2088
- Slabicki, M., Theis, M., Krastev, D. B., Samsonov, S., Mundwiller, E., Junqueira, M., et al. (2010). A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. *PLoS Biol.* 8:e1000408. doi: 10.1371/journal.pbio.1000408
- Sleeth, K. M., Sørensen, C. S., Issaeva, N., Dziegielewska, J., Bartek, J., and Helleday, T. (2007). RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. *J. Mol. Biol.* 373, 38–47. doi: 10.1016/j.jmb.2007.07.068
- Smolka, M. B., Albuquerque, C. P., Chen, S.-H., and Zhou, H. (2007). Proteome-wide identification of in vivo targets of DNA damage checkpoint kinases. *Proc. Natl. Acad. Sci. U.S.A.* 104, 10364–10369. doi: 10.1073/pnas.0701622104
- Sneed, P. K., Stauffer, P. R., McDermott, M. W., Diederich, C. J., Lamborn, K. R., Prados, M. D., et al. (1998). Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. *Int. J. Radiat. Oncol. Biol. Phys.* 40, 287–295. doi: 10.1016/S0360-3016(97)00731-1
- Sørensen, C. S., Hansen, L. T., Dziegielewska, J., Syljuåsen, R. G., Lundin, C., Bartek, J., et al. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. *Nat. Cell Biol.* 7, 195–201. doi: 10.1038/ncb1212
- Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* 102, 15545–15550. doi: 10.1073/pnas.0506580102
- Suzuki, A., de la Pompa, J. L., Hakem, R., Elia, A., Yoshida, R., Mo, R., et al. (1997). Brca2 is required for embryonic cellular proliferation in the mouse. *Genes Dev.* 11, 1242–1252. doi: 10.1101/gad.11.10.1242
- Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., and Taniguchi, T. (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. *Cancer Res.* 68, 2581–2586. doi: 10.1158/0008-5472.CAN-08-0088
- Symington, L. S., and Gautier, J. (2011). Double-strand break end resection and repair pathway choice. *Annu. Rev. Genet.* 45, 247–271. doi: 10.1146/annurev-genet-110410-132435
- Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., et al. (2008). “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *J. Clin. Oncol.* 26, 5530–5536. doi: 10.1200/JCO.2008.16.1703
- Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., et al. (2003). Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. *Nat. Med.* 9, 568–574. doi: 10.1038/nm852
- Trenz, K., Smith, E., Smith, S., and Costanzo, V. (2006). ATM and ATR promote Mre11 dependent restart of collapsed replication forks and prevent accumulation of DNA breaks. *EMBO J.* 25, 1764–1774. doi: 10.1038/sj.emboj.76.01045
- Trojanek, J., Ho, T., Del Valle, L., Nowicki, M., Wang, J. Y., Lassak, A., et al. (2003). Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. *Mol. Cell. Biol.* 23, 7510–7524. doi: 10.1128/MCB.23.21.7510-7524.2003
- Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., et al. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. *EMBO J.* 27, 1368–1377. doi: 10.1038/emboj.2008.61
- Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., et al. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. *Oncogene* 26, 2126–2132. doi: 10.1038/sj.onc.1210014
- Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 376, 235–244. doi: 10.1016/S0140-6736(10)60892-6
- Urbanska, K., Pannizzo, P., Lassak, A., Gualco, E., Surmacz, E., Croul, S., et al. (2009). Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. *J. Cell. Physiol.* 219, 392–401. doi: 10.1002/jcp.21683
- van der Zee, J., González González, D., van Rhooon, G. C., van Dijk, J. D., van Putten, W. L., and Hart, A. A. (2000). Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch deep hyperthermia group. *Lancet* 355, 1119–1125. doi: 10.1016/S0140-6736(00)02059-6
- van Vugt, M. A. T. M., and Medema, R. H. (2005). Getting in and out of mitosis with Polo-like kinase-1. *Oncogene* 24, 2844–2859. doi: 10.1038/sj.onc.1208617
- Vaziri, S. A. J., Hill, J., Chikamori, K., Grabowski, D. R., Takigawa, N., Chawla-Sarkar, M., et al. (2005). Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. *Mol. Cancer Ther.* 4, 1880–1890. doi: 10.1158/1535-7163.MCT-05-0222
- Vernon, C. C., Hand, J. W., Field, S. B., Machin, D., Whaley, J. B., van der Zee, J., et al. (1996). Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. *Int. J. Radiat. Oncol. Biol. Phys.* 35, 731–744. doi: 10.1016/0360-3016(96)00154-X
- Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., et al. (2011). An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. *Ann. Oncol.* 22, 1561–1570. doi: 10.1093/annonc/mdq624
- Wang, H., Shi, L. Z., Wong, C. C. L., Han, X., Hwang, P. Y.-H., Truong, L. N., et al. (2013). The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair. *PLoS genet.* 9:e1003277. doi: 10.1371/journal.pgen.1003277
- Willers, H., Taghian, A. G., Luo, C.-M., Treszezamsky, A., Sgroi, D. C., and Powell, S. N. (2009). Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. *Mol. Cancer Res.* 7, 1304–1309. doi: 10.1158/1541-7786.MCR-09-0149
- Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., et al. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science* 265, 2088–2090. doi: 10.1126/science.8091231
- Wyman, C., Ristic, D., and Kanaar, R. (2004). Homologous recombination-mediated double-strand break repair. *DNA Repair* 3, 827–833. doi: 10.1016/j.dnarep.2004.03.037
- Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., et al. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. *Mol. Cell* 3, 389–395. doi: 10.1016/S1097-2765(00)80466-9
- Yata, K., Lloyd, J., Maslen, S., Bleuyard, J.-Y., Skehel, M., Smerdon, S. J., et al. (2012). Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. *Mol. Cell* 45, 371–383. doi: 10.1016/j.molcel.2011.12.028
- Yu, X., and Chen, J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. *Mol. Cell. Biol.* 24, 9478–9486. doi: 10.1128/MCB.24.21.9478-9486.2004
- Yuan, S. S. F., Chang, H. L., Hou, M. F., Chan, T. F., Kao, Y. H., Wu, Y. C., et al. (2002). Neocarzinostatin induces Mre11 phosphorylation and focus formation through an ATM- and NBS1-dependent mechanism. *Toxicology* 177, 123–130. doi: 10.1016/S0300-483X(02)00220-2
- Zaidi, S., McLaughlin, M., Bhide, S. A., Eccles, S. A., Workman, P., Nutting, C. M., et al. (2012). The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. *PLoS ONE* 7:e35436. doi: 10.1371/journal.pone.0035436

- Zhang, J., Willers, H., Feng, Z., Ghosh, J. C., Kim, S., Weaver, D. T., et al. (2004). Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. *Mol. Cell. Biol.* 24, 708–718. doi: 10.1128/MCB.24.2.708-718.2004
- Zhang, N., Kaur, R., Lu, X., Shen, X., Li, L., and Legerski, R. J. (2005). The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. *J. Biol. Chem.* 280, 40559–40567. doi: 10.1074/jbc.M508453200
- Zhao, S., Weng, Y. C., Yuan, S. S., Lin, Y. T., Hsu, H. C., Lin, S. C., et al. (2000). Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. *Nature* 405, 473–477. doi: 10.1038/35013083
- Zimmermann, M., Lotterberger, F., Buonomo, S. B., Sfeir, A., and de Lange, T. (2013). 53BP1 regulates DSB repair using Rif1 to control 5' end resection. *Science* 339, 700–704. doi: 10.1126/science.1231573
- Zou, L., and Elledge, S. J. (2003). Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 300, 1542–1548. doi: 10.1126/science.1083430
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Copyright © 2015 Krajewska, Fehrmann, de Vries and van Vugt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.